Kenneth D. Aldape

Kenneth D. Aldape's AcademicInfluence.com Rankings

Kenneth D. Aldape

Philosophy

#4716

World Rank

#7336

Historical Rank

Logic

#2121

World Rank

#3042

Historical Rank

philosophy Degrees

Kenneth D. Aldape

Biology

#6229

World Rank

#8899

Historical Rank

Computational Biology

#106

World Rank

#106

Historical Rank

Molecular Biology

#629

World Rank

#644

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Kenneth D. Aldape's Degrees

Doctorate Medicine University of Texas Southwestern Medical Center

Why Is Kenneth D. Aldape Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kenneth D. Aldape's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008) (5775)
The Somatic Genomic Landscape of Glioblastoma (2013) (3693)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. (2006) (2881)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (2015) (2211)
A randomized trial of bevacizumab for newly diagnosed glioblastoma. (2014) (2145)
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (2010) (2121)
Comprehensive molecular characterization of urothelial bladder carcinoma (2014) (1748)
Comprehensive molecular characterization of clear cell renal cell carcinoma (2013) (1724)
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. (2012) (1532)
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma (2016) (1474)
DNA methylation-based classification of central nervous system tumours (2018) (1461)
Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy (1995) (955)
Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth (2015) (898)
Epidemiology and molecular pathology of glioma (2006) (864)
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation (2011) (835)
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. (2013) (820)
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. (2015) (782)
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. (2013) (771)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. (2014) (744)
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. (2010) (715)
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect (2012) (650)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma (2012) (647)
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. (2011) (626)
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs (2016) (608)
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. (2006) (546)
International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading (2014) (514)
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. (2005) (508)
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy (2014) (507)
cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” (2018) (492)
Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. (1995) (491)
Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients (2005) (490)
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge (2014) (472)
The transcriptional network for mesenchymal transformation of brain tumors (2009) (461)
The integrated landscape of driver genomic alterations in glioblastoma (2013) (442)
PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis (2012) (433)
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 (2006) (428)
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules (2008) (428)
Challenges to curing primary brain tumours (2019) (414)
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. (2011) (410)
Activation of stat3 in human melanoma promotes brain metastasis. (2006) (389)
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. (2003) (387)
Expression of nitric oxide synthase in human central nervous system tumors. (1995) (382)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. (2003) (375)
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. (2008) (375)
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. (2020) (367)
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. (2018) (356)
MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance (2009) (353)
A multigene predictor of outcome in glioblastoma. (2010) (353)
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. (2014) (350)
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. (2011) (333)
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. (2005) (331)
FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. (2006) (325)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. (2010) (323)
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. (2011) (318)
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. (2007) (316)
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. (2007) (314)
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. (2007) (302)
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. (2013) (295)
cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading (2020) (293)
Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. (2001) (288)
A model of molecular interactions on short oligonucleotide microarrays (2003) (277)
Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance (2004) (273)
An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. (1998) (267)
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. (2001) (265)
Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. (2016) (264)
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas (2015) (261)
PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis (2014) (260)
TERT Promoter Mutations and Risk of Recurrence in Meningioma. (2016) (259)
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas (2020) (253)
EGFR overexpression and radiation response in glioblastoma multiforme. (2001) (248)
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. (2011) (248)
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO (2015) (241)
Detection of human cytomegalovirus in different histological types of gliomas (2008) (240)
EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. (2009) (239)
PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. (2005) (237)
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma (2009) (234)
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities (2015) (230)
Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. (2001) (229)
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR (2004) (226)
LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS (2019) (223)
The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants (2016) (220)
Using the molecular classification of glioblastoma to inform personalized treatment (2014) (215)
Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. (2000) (210)
YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma (2005) (208)
Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms (2006) (208)
Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. (2010) (202)
Analyses of Resected Human Brain Metastases of Breast Cancer Reveal the Association between Up-Regulation of Hexokinase 2 and Poor Prognosis (2009) (201)
The natural history of EGFR and EGFRvIII in glioblastoma patients (2005) (200)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Gene expression and angiotropism in primary CNS lymphoma. (2006) (197)
Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics (2014) (196)
Genetic determinants of malignancy in a mouse model for oligodendroglioma. (2003) (195)
PKM2 regulates chromosome segregation and mitosis progression of tumor cells. (2014) (193)
Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma (2006) (193)
Defining prognosis for women with breast cancer and CNS metastases by HER2 status. (2008) (189)
Association of an ERCC1 polymorphism with adult-onset glioma. (2000) (188)
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. (2013) (186)
Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells (2007) (180)
Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas (2013) (176)
EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. (2012) (174)
Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses (2014) (173)
Polymorphisms of DNA Repair Genes and Risk of Glioma (2004) (172)
Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. (2001) (170)
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. (2007) (167)
Germline mutations in shelterin complex genes are associated with familial glioma. (2015) (167)
Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class (2013) (164)
FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. (2009) (159)
Therapeutic Targeting of Ependymoma as Informed by Oncogenic Enhancer Profiling (2017) (157)
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma (2009) (157)
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma (2011) (152)
Identification of Causal Genetic Drivers of Human Disease through Systems-Level Analysis of Regulatory Networks (2014) (150)
Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target (2014) (149)
Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care (2017) (147)
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. (2007) (146)
Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. (2002) (146)
Abnormal Expression of REST/NRSF and Myc in Neural Stem/Progenitor Cells Causes Cerebellar Tumors by Blocking Neuronal Differentiation (2006) (146)
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. (2011) (145)
Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. (2010) (145)
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. (2012) (144)
The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain. (2009) (143)
Association and Interactions between DNA Repair Gene Polymorphisms and Adult Glioma (2009) (142)
HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors (2009) (140)
NFKBIA deletion in glioblastomas. (2011) (140)
Expression of Activated Signal Transducer and Activator of Transcription 3 Predicts Expression of Vascular Endothelial Growth Factor in and Angiogenic Phenotype of Human Gastric Cancer (2005) (138)
Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma (2004) (138)
Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 (2008) (138)
Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. (2001) (136)
The Somatic Genomic Landscape of Glioblastoma (2014) (135)
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. (2018) (134)
A prognostic gene expression signature in infratentorial ependymoma (2012) (133)
Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. (2011) (131)
The Mitosis-Specific Antibody Anti-Phosphohistone-H3 (PHH3) Facilitates Rapid Reliable Grading of Meningiomas According to WHO 2000 Criteria (2004) (129)
GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. (2014) (129)
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. (2019) (128)
Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors (2011) (128)
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. (2014) (127)
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. (2016) (127)
Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3 (2008) (127)
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). (2013) (124)
Assessment and Prognostic Significance of Mitotic Index Using the Mitosis Marker Phospho-histone H3 in Low and Intermediate-grade Infiltrating Astrocytomas (2006) (123)
Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. (2011) (122)
Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. (2002) (120)
RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). (2011) (119)
Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. (2010) (119)
Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes (2020) (119)
Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma (2014) (118)
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. (2008) (117)
Small Cell Architecture—A Histological Equivalent of EGFR Amplification in Glioblastoma Multiforme? (2001) (115)
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. (2006) (115)
A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics (2017) (114)
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial (2018) (113)
cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors (2020) (112)
Tumour suppressor TRIM33 targets nuclear β-catenin degradation (2014) (112)
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma (2020) (110)
Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (2016) (109)
Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma (2007) (108)
Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. (2011) (108)
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors (2005) (108)
Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma (2017) (107)
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. (2012) (106)
A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. (2010) (104)
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). (2015) (104)
Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution (2013) (102)
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium (2018) (102)
A clinically applicable integrative molecular classification of meningiomas (2021) (102)
VEGF Trap induces antiglioma effect at different stages of disease. (2008) (101)
Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitination by USP22 (2016) (100)
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. (2013) (99)
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. (2015) (98)
DNA hypermethylation within TERT promoter upregulates TERT expression in cancer (2018) (98)
The genomic landscape of schwannoma (2016) (97)
Clinical actionability enhanced through deep targeted sequencing of solid tumors. (2015) (96)
Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. (2010) (96)
Manganese superoxide dismutase expression in human central nervous system tumors. (1996) (95)
Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells (2005) (94)
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? (2011) (93)
Lysophosphatidic acid production and action: Validated targets in cancer? (2004) (93)
Mitotic Index is an Independent Predictor of Recurrence‐Free Survival in Meningioma (2015) (88)
ERCC1 and ERCC2 polymorphisms and adult glioma. (2005) (87)
Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. (2006) (87)
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays (2006) (87)
Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. (2013) (85)
Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours (2014) (85)
Imaging and diagnostic advances for intracranial meningiomas. (2019) (83)
Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma (2014) (81)
Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. (2012) (80)
A model of molecular interactions on short oligonucleotide microarrays (2003) (79)
FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. (2010) (77)
Advances in multidisciplinary therapy for meningiomas. (2019) (77)
Conversion of myoblasts to physiologically active neuronal phenotype. (2004) (76)
Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma (2006) (76)
Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. (2016) (75)
Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes (2014) (75)
Long-term Anti-inflammatory and Antihistamine Medication Use and Adult Glioma Risk (2008) (75)
Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. (2006) (75)
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas (2011) (75)
Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth (2007) (75)
The molecular epidemiology of gliomas in adults. (2005) (74)
History of chickenpox and shingles and prevalence of antibodies to varicella-zoster virus and three other herpesviruses among adults with glioma and controls. (2005) (74)
MGMT Status as a Clinical Biomarker in Glioblastoma. (2020) (73)
A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma (2018) (73)
Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. (2011) (72)
Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays (2008) (72)
Tissue microdissection and degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors. (2001) (71)
Arresting tissue invasion of a parasite by protease inhibitors chosen with the aid of computer modeling. (1991) (71)
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. (2020) (71)
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. (2013) (70)
Molecular predictors in glioblastoma: toward personalized therapy. (2008) (70)
Tie2/TEK Modulates the Interaction of Glioma and Brain Tumor Stem Cells with Endothelial Cells and Promotes an Invasive Phenotype (2010) (70)
Acquired immunodeficiency syndrome-associated T-cell lymphoma: evidence for human immunodeficiency virus type 1-associated T-cell transformation. (1992) (70)
Expression of the Receptor Tyrosine Kinase Tie2 in Neoplastic Glial Cells Is Associated with Integrin β1-Dependent Adhesion to the Extracellular Matrix (2006) (70)
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum (2002) (70)
Heterogeneity within the PF-EPN-B ependymoma subgroup (2018) (69)
Bayesian ensemble methods for survival prediction in gene expression data (2011) (69)
Molecular Features of Adult Glioma Associated with Patient Race/Ethnicity, Age, and a Polymorphism in O6-Methylguanine-DNA-Methyltransferase (2005) (68)
αvβ8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion (2013) (67)
Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway (2012) (67)
Phosphorylated Pak1 Level in the Cytoplasm Correlates with Shorter Survival Time in Patients with Glioblastoma (2007) (67)
Molecular and translational advances in meningiomas. (2019) (67)
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525 (2017) (67)
Ethnicity delineates different genetic pathways in malignant glioma. (2001) (65)
Localization of the Neuronal Class III β‐Tubulin in Oligodendrogliomas: Comparison with Ki‐67 Proliferative Index and 1p/19q Status (2002) (65)
Predictors of Survival among Pediatric and Adult Ependymoma Cases: A Study Using Surveillance, Epidemiology, and End Results Data from 1973 to 2007 (2012) (63)
Interlaboratory comparison of IDH mutation detection (2013) (63)
Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. (2005) (63)
Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. (2016) (63)
Issues of Diagnostic Review in Brain Tumor Studies: From the Brain Tumor Epidemiology Consortium (2008) (63)
Naegleria fowleri: characterization of a secreted histolytic cysteine protease. (1994) (63)
CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. (2003) (62)
Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. (2013) (62)
cIMPACT‐NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification (2017) (62)
Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy (2006) (62)
Cladosporium trichoides cerebral phaeohyphomycosis in a liver transplant recipient. Report of a case. (1991) (62)
Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas (2017) (61)
New strategies in melanoma: molecular testing in advanced disease. (2012) (61)
Lambrolizumab induced central nervous system (CNS) toxicity (2014) (61)
Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. (2010) (60)
Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. (2015) (60)
World Health Organization 2016 Classification of Central Nervous System Tumors. (2018) (59)
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice (2015) (59)
DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status (2015) (59)
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. (2015) (58)
Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS) (2003) (58)
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813 (2016) (58)
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status (2006) (57)
Glioma progression is shaped by genetic evolution and microenvironment interactions (2022) (56)
Grade II astrocytomas are subgrouped by chromosome aberrations. (2003) (56)
Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas (2012) (55)
Polymorphisms in the Interleukin-4 Receptor Gene are Associated with Better Survival in Patients with Glioblastoma (2008) (55)
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. (2021) (55)
Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor (2012) (55)
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients (2012) (54)
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients (2015) (54)
CIC protein instability contributes to tumorigenesis in glioblastoma (2019) (54)
Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. (2006) (53)
cIMPACT‐NOW: a practical summary of diagnostic points from Round 1 updates (2019) (53)
Selective repression of YKL‐40 by NF‐κB in glioma cell lines involves recruitment of histone deacetylase‐1 and ‐2 (2008) (53)
Epidermal Growth Factor (EGF)-enhanced Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression Promotes Macrophage and Glioblastoma Cell Interaction and Tumor Cell Invasion* (2013) (53)
Mir-21–Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact (2015) (53)
Insights From Molecular Profiling of Adult Glioma. (2017) (52)
The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma (2014) (51)
Initial treatment patterns over time for anaplastic oligodendroglial tumors. (2012) (51)
Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated (2021) (51)
Cellular adhesion regulates p53 protein levels in primary human keratinocytes. (1997) (51)
Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma (2016) (50)
EGFR and EGFRvIII in glioblastoma: partners in crime. (2013) (50)
Glutathione-S-transferase variants and adult glioma. (2004) (50)
Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells (2015) (49)
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. (2010) (49)
Erratum: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma (Neuro-Oncology (2010) 12:2 (116-121)) (2010) (49)
Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477)) (2014) (49)
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. (2014) (48)
Molecular epidemiology of glioblastoma. (2003) (48)
The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration (2006) (48)
The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. (2015) (48)
Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System (2013) (48)
Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. (2007) (48)
Forkhead Box M1 Is Regulated by Heat Shock Factor 1 and Promotes Glioma Cells Survival under Heat Shock Stress* (2012) (47)
Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma (2006) (47)
Hemorrhage and VEGF Expression in a Case of Primary CNS Lymphoma (2002) (46)
Aggregation of Cancer in First-Degree Relatives of Patients with Glioma (2007) (46)
Nuclear EGFRvIII‐STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl‐XL promoter (2013) (46)
Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity (2009) (46)
Loss of Heterozygosity of Chromosome 3p21 Is Associated with Mutant TP53 and Better Patient Survival in Non–Small-Cell Lung Cancer (2004) (46)
Gli1‐induced deubiquitinase USP48 aids glioblastoma tumorigenesis by stabilizing Gli1 (2017) (45)
Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma (2014) (45)
Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1‐deficient non‐rhabdoid tumor with favorable long‐term outcome (2017) (45)
Adult brainstem gliomas: Correlation of clinical and molecular features (2015) (43)
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity (2014) (43)
Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. (2016) (43)
Beyond grade: molecular pathology of malignant gliomas. (2009) (43)
Exploratory Analysis of the Copy Number Alterations in Glioblastoma Multiforme (2008) (42)
Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. (2016) (42)
Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome (2005) (41)
Sex differences in oncogenic mutational processes (2019) (41)
RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). (2016) (41)
Role of the b subunit of the Escherichia coli proton-translocating ATPase. A mutagenic analysis. (1985) (40)
Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. (2006) (40)
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells (2018) (40)
Intramedullary and extramedullary solitary fibrous tumor of the cervical spine. Case report and review of the literature. (2004) (39)
Glutathione S‐transferase polymorphisms are associated with survival in anaplastic glioma patients (2010) (39)
Elevated Phospho-S6 Expression Is Associated with Metastasis in Adenocarcinoma of the Lung (2008) (38)
Phase 1 lead‐in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma (2018) (38)
Genome‐wide analysis of DNA copy number alterations and loss of heterozygosity in intracranial germ cell tumors (2014) (38)
NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma (2016) (36)
Comparison of gadopentetate dimeglumine and albumin‐(Gd‐DTPA)30 for microvessel characterization in an intracranial glioma model (1998) (35)
Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. (2007) (34)
FIRST-IN-HUMAN PHASE I CLINICAL TRIAL OF ONCOLYTIC DELTA-24-RGD (DNX-2401) WITH BIOLOGICAL ENDPOINTS: IMPLICATIONS FOR VIRO- IMMUNOTHERAPY (2014) (34)
Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas (2012) (33)
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma (2016) (33)
The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care (2019) (32)
A Mosaic Mouse Model of Astrocytoma Identifies αvβ8 Integrin as an Essential Regulator of Tumor-Induced Angiogenesis (2010) (32)
Dendritic cell vaccines for high-grade gliomas (2018) (32)
In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression (2020) (32)
CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design. (2020) (31)
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. (2015) (30)
Loss of H3K27me3 in meningiomas. (2021) (30)
Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). (2013) (30)
High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma (2020) (30)
EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis. (2018) (29)
P16 deletion and mutation analysis in human brain tumors (1997) (29)
Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts (2011) (29)
The prognostic value of neurologic function in astrocytic spinal cord glioma. (2003) (28)
Distinct pathways in the pathogenesis of sebaceous carcinomas implicated by differentially expressed microRNAs. (2015) (28)
Risk factors for oligodendroglial tumors: a pooled international study. (2011) (28)
Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing (2014) (27)
Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: implications for combined modality therapy. (1998) (27)
A change at the helm of Neuro-Oncology. (2018) (27)
Sox2: regulation of expression and contribution to brain tumors. (2016) (27)
Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting (2015) (27)
Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. (2014) (27)
Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community (2016) (26)
Erratum: A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases (S0092867418301156 (2018) 172(5) (1050–1062.e14) (S0092867418301156) (10.1016/j.cell.2018.01.038)) (2018) (26)
PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion (2019) (26)
Intratumoral Morphologic and Molecular Heterogeneity of Rhabdoid Renal Cell Carcinoma: Challenges for Personalized Therapy (2015) (26)
Attenuated Expression of DFFB is a Hallmark of Oligodendrogliomas with 1p-Allelic Loss (2005) (26)
Systematic Cell Line-Based Identification of Drugs Modifying ACE2 Expression (2020) (25)
The role of neuropathology in the management of patients with diffuse low grade glioma (2015) (25)
Identification of Causal Genetic Drivers of Human Disease through Systems-Level Analysis of Regulatory Networks (2016) (25)
Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial. (2004) (25)
A case of soft tissue metastasis from glioblastoma and review of the literature (2011) (24)
Sarcomatous Change After Sellar Irradiation in a Growth Hormone-Secreting Pituitary Adenoma (2003) (23)
CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III Randomized Study of RT vs. RT+TMZ vs. TMZ for Newly Diagnosed 1p/19q-Codeleted Anaplastic Oligodendroglial Tumors. Analysis of Patients Treated on the Original Protocol Design (PL02.005) (2016) (23)
ACVR1 mutations and the genomic landscape of pediatric diffuse glioma (2014) (23)
Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature (2017) (23)
Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. (2012) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. (2012) (22)
Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. (2021) (22)
Caspase-3 Cleavage Links δ-Catenin to the Novel Nuclear Protein ZIFCAT* (2011) (22)
Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study (2007) (21)
Atypical meningioma-is it time to standardize surgical sampling techniques? (2016) (21)
Brain metastases from papillary thyroid carcinomas (2013) (21)
TNFα secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy (2021) (21)
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations (2021) (21)
Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry (2015) (21)
Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1 (2020) (20)
Radiotherapy (RT) Dose-intensification (DI) Using Intensity-modulated RT (IMRT) versus Standard-dose (SD) RT with Temozolomide (TMZ) in Newly Diagnosed Glioblastoma (GBM): Preliminary Results of NRG Oncology BN001 (2020) (20)
Targeted Sequencing in Chromosome 17q Linkage Region Identifies Familial Glioma Candidates in the Gliogene Consortium (2015) (20)
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. (2014) (20)
A gene expression signature predicts recurrence-free survival in meningioma (2018) (20)
Proteomic analysis of meningiomas reveals clinically-distinct molecular patterns. (2019) (20)
ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) (2019) (20)
Comprehensive mutation analysis in NRG Oncology/RTOG 9813: A phase III trial of RT + TMZ vs RT + nu for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant). (2016) (20)
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02 (2017) (19)
Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray (2017) (19)
Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). (2014) (19)
Clinical impact of combined epigenetic and molecular analysis of pediatric low grade gliomas. (2020) (19)
Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. (2019) (19)
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma (2019) (19)
The Use of Global Profiling in Biomarker Development for Gliomas (2011) (19)
Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. (2015) (18)
Temozolomide as a vaccine adjuvant in GBM (2007) (18)
Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma (2020) (17)
Brain tumor stem cells. (2008) (17)
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma (2021) (17)
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer (2014) (17)
High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors (2010) (16)
Cowden Disease with Lhermitte-Duclos Disease: Case Report (2004) (16)
ATCT-16CODEL (ALLIANCE-N0577; EORTC-26081/2208; NRG-1071; NCIC-CEC-2): PHASE III RANDOMIZED STUDY OF RT VS. RT + TMZ VS. TMZ FOR NEWLY DIAGNOSED 1p/19q-CODELETED ANAPLASTIC GLIOMA. ANALYSIS OF PATIENTS TREATED ON THE ORIGINAL PROTOCOL DESIGN. (2015) (16)
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. (2014) (16)
C11orf95–RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma (2015) (16)
Real‐time Quantitative Polymerase Chain Reaction: A Potential Tool for Genetic Analysis in Neuropathology (2002) (16)
Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression (2020) (15)
AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL (2014) (15)
Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1 (2021) (15)
Molecular Signatures for Tumor Classification: An Analysis of The Cancer Genome Atlas Data. (2017) (15)
NT-18PHASE I CLINICAL TRIAL OF ONCOLYTIC VIRUS DELTA-24-RGD (DNX-2401) WITH BIOLOGICAL ENDPOINTS: IMPLICATIONS FOR VIRO-IMMUNOTHERAPY. (2014) (15)
PCR Techniques in Characterizing DNA Methylation. (2016) (14)
Epigenomic, genomic, and transcriptomic landscape of schwannomatosis (2020) (14)
Utility of Chromogenic In Situ Hybridization (CISH) for Detection of EGFR Amplification in Glioblastoma: Comparison With Fluorescence In Situ Hybridization (FISH) (2008) (14)
Aberrant NF-kappaB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor. (2008) (14)
Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas (2019) (14)
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas (2017) (14)
Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma (2011) (14)
RADIATION THERAPY ONCOLOGY GROUP RTOG 0825 PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS BEVACIZUMAB VERSUS CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2009) (14)
Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and WNT. (2020) (13)
NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma (2020) (13)
Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. (2005) (13)
Prognostic and predictive markers in glioma and other neuroepithelial tumors. (2008) (12)
A role for matrix remodelling proteins in invasive and malignant meningiomas (2014) (12)
Gamma-radiation sensitivity and polymorphisms in RAD51L1 modulate glioma risk. (2010) (12)
Inhibition of LSD 1 sensitizes glioblastoma cells to histone deacetylase inhibitors (2011) (11)
Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non‐sarcomatoid renal carcinomas (2015) (11)
RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma. (2011) (11)
A novel ATXN1-DUX4 fusion expands the spectrum of ‘CIC-rearranged sarcoma’ of the CNS to include non-CIC alterations (2021) (11)
Familial Medulloblastoma: Case Report of One Family and Review of the Literature (2002) (11)
ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features. (2019) (11)
Minimalist approaches to cancer tissue-of-origin classification by DNA methylation (2020) (11)
Characteristics and survival of patients with advanced cancer and p53 mutations (2014) (11)
Mouse models of human cancers (part 3). (2004) (11)
Tumor-derived mesenchymal stem cells in human gliomas: Isolation and biological properties (2008) (10)
DNA Methylation based prognostic subtypes of chordoma tumors in tissue and plasma. (2021) (10)
Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. (2004) (10)
Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme (2007) (10)
Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma (2017) (10)
Polysomy is associated with poor outcome in 1p19q co-deleted oligodendroglial tumors. (2019) (10)
5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma (2018) (10)
c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein (2020) (9)
Corrigendum: Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation (2017) (9)
The molecular landscape of diffuse glioma and prospects for biomarker development. (2013) (9)
Molecular tools: biology, prognosis, and therapeutic triage. (2010) (9)
DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. (2019) (9)
GE-41COMPREHENSIVE AND INTEGRATIVE GENOMIC CHARACTERIZATION OF DIFFUSE LOWER GRADE GLIOMAS (2014) (9)
Aberrant p 53 , mdm 2 , and Proliferation Differ in Glioblastomas from Long-Term Compared with Typical Survivors 1 (2002) (9)
Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression‐free survival in patients treated with DFMO–PCV chemotherapy (2007) (9)
Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). (2015) (9)
Multigene sets for clinical application in glioma. (2011) (8)
A regulatory network of canonical nuclear factor-κB activation predicts high-grade glioma outcome (2007) (8)
Abstract 936: Comprehensive and integrative genomic characterization of diffuse lower grade gliomas (2014) (8)
Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. (2016) (8)
Models of malignant glioma (2006) (7)
Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas (2021) (7)
BRAF V600E mutant oligodendroglioma‐like tumors with chromosomal instability in adolescents and young adults (2020) (7)
PIK3CA mutations in meningioma. (2016) (7)
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect (2012) (7)
Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. (2016) (7)
LAB-ANGIOGENESIS AND INVASION (2012) (6)
Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop. (2020) (6)
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials (2013) (6)
Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. (2021) (6)
Effect of a small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells (2008) (6)
Association of an ERCC 1 Polymorphism with Adult-Onset Glioma 1 (2000) (6)
Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis. (2007) (5)
CD44 as a prognostic and predictive marker for GBM. (2011) (5)
Additive effect of the combination of 5-aza-2’-deoxycytidine and valproic acid in leukemia cell systems (2004) (5)
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. (2020) (5)
IDH1 status and survival benefit from surgical resection of enhancing and nonenhancing tumor in malignant astrocytomas. (2012) (5)
Molecular biology of brain tumors. (2012) (5)
Erratum: EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis (Molecular Cell (2012) 48(5) (771–784)(S1097276512008283)(10.1016/j.molcel.2012.09.028)) (2012) (5)
A dural-based spindle cell neoplasm characterized by a novel MN1-KMT2A fusion gene. (2019) (5)
ACTR-37. PREDICTIVE SIGNIFICANCE OF IDH1/2 MUTATION AND 1p/19q CO-DELETION STATUS IN A POST-HOC ANALYSIS OF NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS (2017) (5)
DICER governs characteristics of glioma stem cells and the resulting tumors in xenograft mouse models of glioblastoma (2016) (5)
Transcription Profiling of Brain Tumors: Tumor Biology and Treatment Stratification (2009) (5)
BI-30CHARACTERIZATION OF L1CAM AS A CLINICAL MARKER FOR THE C11orf95-RELA FUSION IN SUPRATENTORIAL EPENDYMOMAS (2014) (5)
NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings. (2020) (5)
TAMI-46. TNFα SECRETED BY GLIOMA ASSOCIATED MACROPHAGES PROMOTES ENDOTHELIAL ACTIVATION AND RESISTANCE AGAINST ANTI-ANGIOGENIC THERAPY (2020) (5)
CMV and glioma--are we there yet? (2014) (5)
RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM) (2011) (4)
Bagged gene shaving for the robust clustering of high-throughput data (2010) (4)
BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. (2013) (4)
NEURO/MEDICAL ONCOLOGY (2013) (4)
Activating NTRK2 and ALK receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: a diagnostic overlap with infant-type hemispheric glioma (2021) (4)
NEXT-GENERATION NEUROPATHOLOGY - IMPROVING DIAGNOSTIC ACCURACY FOR BRAIN TUMORS USING DNA METHYLATION ARRAY-BASED MOLECULAR PROFILING (2014) (4)
Not expecting the unexpected: diacylglycerol kinase alpha as a cancer target. (2013) (4)
Next-generation molecular diagnostics. (2016) (4)
MGMT Promoter Methylation Status Independently Predicts Overall Survival in Anaplastic Astrocytoma in NRG Oncology/RTOG 9813: A Phase 3 Trial of Radiation Plus Nitrosourea Versus Radiation Plus Temozolomide (2017) (4)
Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology (2022) (4)
MGMT Promoter Methylation is an Independent Prognostic Factor in the Absence of Alkylating Chemotherapy in Glioblastoma (2008) (4)
Adult High-Grade (Diffuse) Glioma (2015) (4)
Erratum: MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance (Clinical Cancer Research (2009) 15 (4622-4629)) (2013) (4)
Metastatic spinal ependymoma presenting as a vestibular schwannoma. Case illustration. (2000) (3)
A Revised RTOG Recursive Partitioning Analysis (RPA) Model for Glioblastoma Based Upon Multiplatform Biomarker Profiles (2012) (3)
ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA) (2015) (3)
IDH mutation testing in gliomas-where do we draw the line? (2017) (3)
Bringing IDH into the Fold. (2016) (3)
The Alliance AMBUSH Trial: Rationale and Design (2022) (3)
The multiforme of glioblastoma. (2018) (3)
ACTR-04. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CO-DELETION, AN INTERGROUP TRIAL (2016) (3)
xpression of Transcription Factor E 2 F 1 and Telomerase in Glioblastomas : Mechanistic Linkage and Prognostic Signi fi cance (2005) (3)
CTNI-29. CODEL: PHASE III TRIAL OF RT ALONE, RT PLUS TMZ, OR TMZ ALONE FOR NEWLY-DIAGNOSED, 1p/19q CODELETED ANAPLASTIC OLIGODENDROGLIOMA. ANALYSIS FROM THE INITIAL STUDY DESIGN. (NCCTG N0577, ALLIANCE) (2020) (3)
Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis. (2020) (2)
Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM). (2012) (2)
MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma. (2009) (2)
Immune cell deconvolution of bulk DNA methylation data reveals an association with methylation class, key somatic alterations, and cell state in glial/glioneuronal tumors (2021) (2)
NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma. (2018) (2)
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients (Journal of Clinical Investigation (2012) 122, 1, (253-266) DOI: 10.1172/JCI59334) (2012) (2)
Erratum: Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis (The Journal of Clinical Investigation (2013) 123:1 (405-417) (DOI: 10.1172/JCI63811) (2014) (2)
OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas (2017) (2)
Challenges and opportunities in meningiomas: recommendations from the International Consortium on Meningiomas. (2019) (2)
RADIATION THERAPY ONCOLOGY GROUP RTOG 0625 A RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB WITH IRINOTECAN OR BEVACIZUMAB WITH TEMOZOLOMIDE IN RECURRENT GLIOBLASTOMA (2009) (2)
Correlation of hexokinase-2 expression with overall survival and potential as a therapeutic target in the treatment of breast cancer brain metastases (2008) (2)
P04.01RELA FUSION DEFINES CLINICOPATHOLOGIC SUBSETS OF SUPRATENTORIAL EPENDYMOMA: A STUDY FROM THE COLLABORATIVE EPENDYMOMA RESEARCH NETWORK (2014) (2)
Human Glioma Diagnosis from Gene Expression Data (2003) (2)
Glut3 Addiction: A Druggable Vulnerability in Glioblastoma. (2017) (2)
Clinical utility of g-cimp and idh1 status as dual prognostic markers in glioblastoma (2011) (2)
Metastatic Papillary Thyroid Carcinoma in Brain: Report of Three Cases (2008) (1)
METB-08INHIBITION OF HEXOKINASE 2 USING TUMOR GLYCOLYSIS INHIBITORS IDENTIFIED THROUGH A DRUG SCREEN INHIBITS GLIOBLASTOMA GROWTH IN VITRO AND IN VIVO (2015) (1)
RTOG 0525: Molecular correlates from randomized phase III trial of newly diagnosed glioblastoma (GBM). (2011) (1)
Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis (2006) (1)
Abstract 4305: Refinement of the glioma cancer stem cell marker profile (2010) (1)
Cross-species identification of cancer-resistance associated genes uncovers their relevance to human cancer risk (2021) (1)
TMIC-17. IMMUNE MICROENVIRONMENT OF NF2-ALTERED RADIATION-INDUCED MENINGIOMAS (2018) (1)
71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES (2020) (1)
ENLIGHT: Pancancer response prediction to targeted and immunotherapies via tumor transcriptomics. (2022) (1)
Abstract B82: Immune signatures of glioblastoma subtypes: Extrapolation from the Cancer Genome Atlas. (2013) (1)
Clinical, Molecular, and Molecular-Clinical Profile (MCP) Exploratory Subset Analysis of RTOG 0525: a Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM) (2011) (1)
Erratum: Lysophosphatidic acid production and action: Validated targets in cancer? (Journal of Cellular Biochemistry (2004) 92 (1115-1140)) (2004) (1)
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma (2021) (1)
Non-skull Base Cranial Meningiomas have a Higher Grade at Recurrence than Skull Base Meningiomas (2009) (1)
NRG Oncology/RTOG 0525 Role of Machine Learning Analytic Tools for Survival Prediction of GBM Patients Using Clinical Parameters (2015) (1)
Acknowledgement of Reviewers 2012 (2013) (1)
PATH-11. PROGNOSTIC SIGNIFICANCE OF EPIGENETIC SUBTYPES AND CpGs ASSOCIATED WITH PROGRESSION TO G-CIMP LOW IN THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON (2020) (1)
Quantitative assessment of AKT activation in melanoma. (2009) (1)
Abstract 5270: IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas (2015) (1)
Phosphorylated Pak 1 Level in the CytoplasmCorrelateswith Shorter SurvivalTime in Patients with Glioblastoma (2007) (1)
Overexpression of Sema 3 E and Sema 5 A in pilocytic astrocytoma (2017) (1)
A BRCA1deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity (2014) (1)
ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA (2015) (1)
Treatment of glioma-bearing mice with VEGF Trap results in significant prolongation of survival (2005) (1)
431 A Revised RTOG Recursive Partitioning Analysis (RPA) Model for Glioblastoma Based Upon Multi-Platform Biomarker Profiles (2012) (1)
Reply to M.C. Chamberlain. (2014) (1)
Erratum: A model of molecular interactions on short oligonucleotide microarrays (Nature Biotechnology (2003) 21 (818-821)) (2003) (1)
Tumor-derived mesenchymal stem cells in human gliomas: Isolation and biological effects (2008) (1)
Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy (2021) (1)
Omics and Prognostic Markers (2010) (1)
Comparison of 2-hydroxyglutarate (2HG) levels in tissue and serum of isocitrate dehydrogenase (IDH)-mutated (MUT) versus wild-type (WT) gliomas. (2017) (1)
Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. (2013) (1)
The NF kappa B pathway as a key mediator of the glioblastoma mesenchymal subtype in glioblastoma stem cells and human tumors. (2012) (1)
Evaluation of Photon and Proton Radiotherapy Plan Quality With the Knowledge-Based Approach in NRG BN001 Clinical Trial (2020) (1)
Impact of IDH-1 Mutation Status on Outcome in Clinical Trials for Recurrent Glioblastoma (P5.255) (2016) (1)
Medical and Neuro-Oncology (2010) (1)
Neuropathology and Molecular Biology of Intracranial Tumors (2007) (1)
GENT-36. THE GENOMIC LANDSCAPE OF SCHWANNOMA (2016) (1)
Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors (2022) (1)
Whole exome precision oncology targeting synthetic lethal vulnerabilities across the tumor transcriptome (2020) (1)
AT-07A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL. (2014) (1)
Medical and Neuro-Oncology (2010) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
Highlights of the inaugural ten - the launch of Neuro-Oncology Advances. (2019) (1)
Histone deacetylase inhibitors (HDACIs) induce HIF-1 transcriptional activity. (2006) (1)
Advances in Brief Akt Pathway Activation Converts Anaplastic Astrocytoma to Glioblastoma Multiforme in a Human Astrocyte Model of Glioma 1 (2001) (1)
Comprehensive mutation analysis in NRG Oncology/RTOG 9802: A phase III study of RT vs RT + PCV in high-risk low-grade gliomas (LGGs). (2016) (1)
GENE-37. PATHWAY ANALYSIS OF RADIATION-INDUCED MENINGIOMAS REVEALS THAT TUMOURS WITH NF2-FUSION HAVE UPREGULATION OF INFLAMMATORY PATHWAYS (2017) (1)
A simple, high-throughput method of protein and label removal from extracellular vesicle samples (2020) (1)
DNA methylation array-based molecular profiling for brain tumor classification (2015) (1)
TUMORIGENICITY IS INDEPENDENT OF DIFFERENTIATION IN GLIOBLASTOMA STEM CELLS (2009) (1)
Omics and Prognostic Markers (2010) (1)
TM-02IDENTIFICATION OF THE AZOLE CLASS OF ANTIFUNGALS AS POTENT INHIBITORS OF HEXOKINASE II MEDIATED TUMOUR METABOLISM IN GLIOBLASTOMA. (2014) (1)
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial ependymoma (2021) (1)
RBTT-11. NRG ONCOLOGY NRG-BN006: A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 AND TOCA FC WITH STANDARD OF CARE COMPARED TO STANDARD OF CARE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2019) (1)
Abstract 4588: Frequency and clinical characteristics ofc-METmutation in malignant melanoma (2012) (1)
CTNI-23. IDH1/2wt ANAPLASTIC GLIOMAS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL: OVERALL SURVIVAL RELATED TO TREATMENT, MGMT STATUS AND MOLECULAR FEATURES OF GLIOBLASTOMA (2020) (1)
A Molecular Signature to Predict Meningioma Recurrence and Progression (2013) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
AT-11CRIBRIFORM NEUROEPITHELIAL TUMOR (CRINET): MOLECULAR CHARACTERIZATION OF A SMARCB1-DEFICIENT NON-RHABDOID TUMOR WITH FAVORABLE LONG-TERM OUTCOME (2016) (0)
GENT-37. THE GENETICS DRIVING RADIATION INDUCED MENINGIOMAS (2016) (0)
154 Genomic Landscape of Radiation-Induced Meningiomas (2017) (0)
OS08.7 The somatic landscape of Schwannoma. (2017) (0)
DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status (2015) (0)
MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS (2016) (0)
Cordero Antibiotic Production and Resistance Ecological Populations of Bacteria Act as Socially Cohesive Units of (2012) (0)
53 Alterations in the epigenetic profile of glioblastoma tumors within hypoxic tumor regions (2018) (0)
Comparison of oncometabolite 2-hydroxyglutarate (2HG) levels in mutant isocitrate dehydrogenase (IDH) versus wild-type (WT) glioma tissues. (2016) (0)
40 Prognostic significance of PD-L1 expression in meningioma for tumor recurrence; associated with hypoxia and NFKB2 activation (2018) (0)
Chromosomal domains of transcriptional activation by PI3K/AKT pathway alterations in glioblastomas (2007) (0)
CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
Abstracts (1926) (0)
TMOD-02. DIFFUSE GLIOMATOSIS IN MOUSE MODEL OF GFAP TISSUE SPECIFIC KNOCK IN OF EGFRvIII AND KNOCK OUT OF p19 ARF (2018) (0)
Abstract 5325: 5-hydroxymethylcytosine profiling identifies differential targeting inIDH1mutant versusIDH1wild-type high-grade gliomas (2018) (0)
2 NEUROPATHOLOGY AND MOLECULAR BIOLOGY OF INTRACRANIAL TUMORS (2019) (0)
Response to Weltman and Fleury Malheiros, re Lassman et al. (2012) (0)
GANGLIOGLIOMA ARISING IN ASSOCIATION WITH AN ANAPLASTIC EPENDYMOMA (1993) (0)
Identification of the Prognostic Signatures for Isocitrate Dehydrogenase Mutant Glioma (2022) (0)
Pathology (1916) (0)
DNA methylation and survival differences associated with the type of IDH mutation in 1p/19q non-codeleted astrocytomas (2020) (0)
46 Integration of multiple platforms to discover idh-mutant glioma subtypes (2018) (0)
Abstract 2467: Podoplanin expressing cancer stem cells show increased resistance to DNA damage induced by ionizing radiation (2011) (0)
PATH-29. COMPARATIVE ANALYSIS OF DNA METHYLATION PROFILES ASSOCIATED WITH IDH-WILDTYPE GLIOMA AND GLIONEURONAL TUMOR SUBTYPES (2020) (0)
CJN volume 30 issue 4 Cover and Front matter (2003) (0)
Technical Advance Detection of 1p and 19q Loss in Oligodendroglioma by Quantitative Microsatellite Analysis, a Real-Time Quantitative Polymerase Chain Reaction Assay (2001) (0)
CCR New Strategies NewStrategies inMelanoma : Molecular Testing in Advanced Disease (2012) (0)
CLIN-MEDICAL + RADIATION THERAPIES (2012) (0)
Abstract 3314: Phenotypic plasticity in glioma stem cells mediated by NFκB signaling (2012) (0)
A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multiplatform biomarker profiles. (2012) (0)
Highlights from the literature (1962) (0)
EPEN-28. HETEROGENEITY WITHIN THE PFB EPENDYMOMA SUBGROUP (2018) (0)
A mesenchymal/stem cell predictor of survival of patients with malignant gliomas. (2010) (0)
Abstract PO-060: Individualized prediction of meningioma recurrence risk over prolonged time periods (2021) (0)
Neuro-oNcology VEGF Trap induces antiglioma effect at different stages of disease (2008) (0)
DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM (2018) (0)
ANGI-11. BONE MARROW-DERIVED MESENCHYMAL STEM CELLS-MEDIATED RADIORESISTANCE IN GLIOBLASTOMA ANGIOGENESIS (2016) (0)
EPCO-12. SINGLE CELL PROFILING OF LONG NON-CODING RNAS IN GLIOMA (2020) (0)
CIC protein instability contributes to tumorigenesis in glioblastoma (2019) (0)
TNFα secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy (2021) (0)
MR-05GLIOMA STEM CELL SPECIFIC microRNA-mRNA INTERACTION NETWORK (2014) (0)
Abstract 5166: Identification of prostate stem cell antigen (PSCA) as a potential marker for lung cancer brain metastasis (2011) (0)
Highlights from the literature (1958) (0)
Epigenomic tumor evolution modeling with single-cell methylation data profiling (2021) (0)
EPCO-04. GENOMIC AND EPIGENOMIC HALLMARKS OF SCHWANNOMATOSIS SCHWANNOMAS (2020) (0)
MS-15THE IMPACT OF HISTOPATHOLOGIC AND RADIOLOGIC CHARACTERISTICS IN CLINICAL OUTCOME OF PATIENTS WHO UNDERWENT SURGERY FOR INTRACRANIAL MENINGIOMAS (2014) (0)
Abstract 5157: Functional and regulatory role of src kinase in podoplanin expressing glioma cancer stem cells (2010) (0)
Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma. (2018) (0)
Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis (2020) (0)
EPIG-13ROBUST MGMT METHYLATION DETECTION USING 450k ARRAY IN CIMP-NEGATIVE GBM (2015) (0)
CARCINOMATOSIS AND CONCURRENT BACTERIAL MENINGITIS IN A PATIENT WITH ESOPHAGEAL ADENOCARCINOMA : A CASE REPORT (2011) (0)
AI-05IMPACT OF GBM MICROENVIRONMENT ON EXPRESSION PROFILE OF BONE MARROW DERIVED PROGENITOR CELLS (2014) (0)
Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis. (2019) (0)
Abstract 5545: MethyMeter®- A quantitative, bisulfite-free DNA methylation assay for improved clinical diagnostic and prognostic analysis of glioma biomarkers in FFPE tumor samples (2012) (0)
GENE-05. UPREGULATION OF ODZ1-MEDIATED INVASION IN THE HYPOXIC TUMOR MICROENVIRONMENT IN GLIOBLASTOMA (2018) (0)
Targeted Disruption of Stat 3 Signaling Inhibits Tumor Growth and Brain Metastases by Caveolin-1 Upregulation (2011) (0)
GENE-15. CHARACTERIZATION OF DIFFERENTIAL 5-HYDROXYMETHYLCYTOSINE IN IDH1 MUTANT VERSUS IDH1 WILD-TYPE HIGH-GRADE GLIOMAS (2017) (0)
CBIO-22DICER AND miRNAs REGULATE GLIOMA STEM CELL CHARACTERISTICS (2015) (0)
Abstract 3688: Akt pathway genes classify GBM into 6 prognostic subgroups with different clinical and molecular features (2012) (0)
Abstract 841: Meningioma subgroups associated with functional genomic elements defined by DNA methylation (2019) (0)
320. Modeling Human Brain Cancer in Transgenic E2F1 Mice (2006) (0)
EPCO-02. MOLECULAR CHARACTERIZATION OF TWO NOVEL MPNST SUBGROUPS IDENTIFIES THERAPEUTIC OPPORTUNITIES (2020) (0)
Chapter 27 – Astroblastoma (2005) (0)
Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab (2022) (0)
CMET-32. DNA METHYLATION ALTERATIONS IN LUNG ADENOCARCINOMAS THAT DEVELOP BRAIN METASTASES (2019) (0)
An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012. (2013) (0)
TMOD-04. A COMPREHENSIVE GENOMIC LANDSCAPE OF GLIOMA SPHEROID CULTURES RECAPITULATES THE HETEROGENEITY OF GLIOBLASTOMA AND IDENTIFIES DNA METHYLATION PREDICTORS OF RADIOTHERAPY RESPONSE (2017) (0)
RAS Mutations Coexist with PIK3CA and MET Mutations in Lacrimal Gland Epithelial Neoplasms (2013) (0)
EG-09EPIGENETIC PROFILING REVEALS A CpG HYPERMETHYLATION PHENOTYPE (CIMP) ASSOCIATED WITH WORSE PROGRESSION-FREE SURVIVAL IN MENINGIOMA. (2014) (0)
CSIG-07. c-Src PHOSPHORYLATES AND INACTIVATES THE CIC TUMOR SUPPRESSOR PROTEIN IN GLIOBLASTOMA (2020) (0)
PDPN+ Tumor Initiating, Treatment Resistant Glioblastoma Cells Promote Radiation Resistance Via PRC2 (2020) (0)
Abstract 978: A regulatory role for TAZ in mesenchymal differentiation of glioblastoma (2011) (0)
Abstract LB-114: Molecular and lineage analysis of glioblastoma stem cells identifies clinically relevant models of glioblatoma (2011) (0)
STEM CELL SPECIFIC microRNA-mRNA INTERACTION NETWORK (2014) (0)
EPIG-05RADIORESISTANCE OF PODOPLANIN-EXPRESSING GLIOMA STEM CELLS IS ASSOCIATED WITH EZH2-DRIVEN POLYCOMB REPRESSIVE COMPLEX ACTIVITY (2015) (0)
MOLECULAR-BASED GRADING IN IDH-MUTANT LOWER GRADE GLIOMAS (2014) (0)
Abstract 1646: A glioblastoma methylation assay (GaMA) developedfrom genomic analysis of glioma spheroid cultures predicts response toradiation therapy in patients with glioblastoma (2016) (0)
A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms. (2020) (0)
NCOG-55. HARMONIZING LANGUAGE TO MAXIMIZE IMPACT: AN UPDATE ON COMMON DATA ELEMENTS FOR MENINGIOMA AND REVIEW OF CLINICAL TRIALS IN MENINGIOMA (2020) (0)
MS-02TRANSCRIPTOME ANALYSIS IDENTIFIES THE PI3K/AKT/mTOR PATHWAY AS A TARGETABLE PATHWAY IN SCHWANNOMA (2014) (0)
Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM). (2013) (0)
Abstract 5147: Trancriptional activation of the glioma stem cell marker podoplanin by the homeobox transcription factor prox1 (2010) (0)
Deletion of NFKBIA in malignant gliomas. (2010) (0)
Abstract PL04-02: Extracellular vesicles as opportunities for integrative or focused liquid biopsy studies (2019) (0)
Use of DNA copy number analysis of grade 2-4 gliomas to reveal differences in molecular ontogeny associated with IDH mutation status. (2013) (0)
Abstract 907: Brain microenvironment induced PTEN loss by microRNAs promotes brain metastasis (2016) (0)
LGG-01. BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENT AND YOUNG ADULT (2019) (0)
MPTH-06. 1p/19q CO-DELETION STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS (2016) (0)
MNGI-04. PATHWAY ANALYSIS OF RADIATION-INDUCED MENINGIOMAS REVEALS UPREGULATION OF INFLAMMATORY PATHWAYS IN TUMORS WITH NF2-FUSION (2017) (0)
Glioma Through the Looking GLASS: the Glioma Longitudinal Analysis consortium, molecular evolution of diffuse gliomas (2017) (0)
Genetic classification of grade 3 and grade 4 astrocytoma with DNA microarrays (2004) (0)
MOMC-3. Hypermethylation and overexpression of HOX genes are poor prognosticators in Lower-Grade Glioma (2021) (0)
Abstract 4795: A novel gene fusion in glioblastoma and a radiation response methylation signature identified by genomic characterization of glioma sphere-forming cells (2015) (0)
Proceedings of the WFNS Neuro-Oncology Committee Workshop Rome 2015 (2016) (0)
ECOA-4. Hypoxia alters the DNA methylation profile of glioblastoma tumor cells (2021) (0)
Retrospective survival comparison of patients with cerebral versus cerebellar glioblastomas (2008) (0)
PDPN marks a subset of aggressive and radiation-resistant glioblastoma cells (2022) (0)
MNGI-12. EXPRESSION OF PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) IN MENINGIOMA: CLINICAL UTILITY FOR PREDICTION OF TUMOR RECURRENCE AND ASSOCIATION WITH HYPOXIC RESPONSE AND NFKB2 ACTIVATION (2018) (0)
From Molecular Pro fi ling of Adult Glioma (2017) (0)
RESICstance is futile-but not in glioblastoma. (2014) (0)
A network of endogenous modulators of canonical nuclear factor-κB activation predicts high-grade glioma outcome (2007) (0)
Abstract B27: TAZ as a regulator of mesenchymal transformation and clinical aggressiveness in gliomas (2010) (0)
Abstract 3094: Epigenetic classification of ependymal brain tumors across age groups (2014) (0)
CBMT-06. LOWER GRADE ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS METABOLICALLY MIMICKING GLIOBLASTOMA (GBM) EXPRESS HIGHER R:S 2-HYDROXYGLUTARATE RATIOS RELATIVE TO NON-GBM-MIMICKING IDH MUTANT GLIOMAS (2018) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
RTHP-07. TRANSCRIPTION FACTOR NETWORKS OF OLIGODENDROGLIOMAS (IDH-MUTANT AND 1p/19q CODELETED) TREATED WITH ADJUVANT RADIOTHERAPY OR OBSERVATION INFORMS PROGNOSIS (2018) (0)
Abstract LB-123: Analyses of anti-cancer testis antigen antibodies in glioma patients treated with Delta-24 oncolytic adenovirus (2012) (0)
Mutations of FH and IDH may induce gliomagenesis by similar mechanisms. (2022) (0)
GENE-26. MOLECULAR CHARACTERIZATION OF BENIGN AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS THAT OCCUR IN SPORADIC AND SYNDROMIC SETTINGS (2018) (0)
brane in Glioblastoma Contributes to PTEN Inactivation (2010) (0)
Needle in a Haystack: Identifying Drivers of Malignant Transformation in Neurofibromas. (2019) (0)
CADD-49. IDENTIFICATION AND VALIDATION OF AZOLES AS HK2 INHIBITORS IN GLIOBLASTOMA IN VITRO AND IN VIVO (2018) (0)
CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM (2020) (0)
Analysis of Patients Receiving Histone Deacetylase Inhibiting Antiepileptic Agents during Radiation Treatment for Glioblastoma (2008) (0)
ANGI-10GLIOMA-ASSOCIATED MACROPHAGES PROMOTE ENDOTHELIAL CELL DYSFUNCTION (2015) (0)
PATH-20. INVESTIGATION OF CLINICALLY AGGRESSIVE SPINAL CORD EPENDYMOMA THROUGH METHYLATION ANALYSIS (2019) (0)
Abstract 1144: Micro RNA profiling of intracranial germ cell tumors (2011) (0)
ABNORMAL P53 EXPRESSION AND RADIOGRAPHICALLY -ASSESSED RADIATION RESPONSE IN GLIOBLASTOMA MULTIFORME (GM) (1998) (0)
Acquired Immunodeficiency Syndrome-Associated T-cel l Lymphoma : Evidence for Human Immunodeficiency Virus Type 1-Associated T-cel l Transformation (2003) (0)
A 64‐year‐old woman with frontal lobe lesion and drug‐resistant epilepsy (2022) (0)
P10.21 2-hydroxyglutarate as a biomarker for IDH mutation in low grade gliomas (2017) (0)
MPTH-22INTEGRATING MOLECULAR MARKERS INTO THE WORLD HEALTH ORGANIZATION (WHO) CLASSIFICATION OF GLIOMAS: SURVEY RESULTS FROM THE SNO MEMBERSHIP (2015) (0)
Clonal Heritability of CTA Expression and Promoter Methylation Patterns In Melanoma Cells: Bases for Epigenetic Therapy? (2008) (0)
AGE AND MOLECULAR SUBGROUPING DETERMINE THE PREDICTIVE VALUE OF PROGNOSTIC MARKERS IN GLIOBLASTOMA MULTIFORME (1999) (0)
Abstract 1889: Next-generation neuropathology - Improving diagnostic accuracy for brain tumors using DNA methylation array-based molecular profiling (2014) (0)
A REGULATORY ROLE FOR TAZ IN PRONEURAL TO MESENCHYMAL DIFFERENTIATION IN GLIOBLASTOMA (2010) (0)
BSCI-26. COMPARATIVE METHYLATION PROFILING OF EGFR MUTANT LUNG ADENOCARCINOMA AND PAIRED BRAIN METASTASIS (2019) (0)
Molecular classification and grading of meningioma (2023) (0)
Clinicopathological correlation (CC) and outcome of breast cancer patients (pts) with resected brain metastasis (BM). (2006) (0)
An intermediate methylation signature is associated with improved patient survival and a distinct global mRNA expression profile in glioblastoma: An interim analysis of The Cancer Genome Atlas data (2008) (0)
Integrated Multi-Omics Characterization of Neurofibromatosis Type 1 Related Peripheral Nerve Sheath Tumors Identifies Two Distinct Malignant Peripheral Nerve Sheath Tumors Subtypes with Sonic Hedgehog or WNT Pathway Activation (2019) (0)
THE TREATMENT-RESISTANT MESENCHYMAL SIGNATURE IN GLIOBLASTOMA DERIVES FROM TUMOR CELLS INDEPENDENT OF STROMA (2014) (0)
O8.10A MODEL FOR RESEARCH INITIATIVES FOR RARE CANCERS: THE COLLABORATIVE EPENDYMOMA RESEARCH NETWORK (CERN). (2014) (0)
Abstract 1789: NFKBIA deletion in malignant gliomas (2010) (0)
ERCC1 and ERCC2 polymorphisms and adult glioma1 (2005) (0)
Genetic Profiling of Oligodendrogliomas (IDH Mutated and 1p19q Co-deleted) Treated with Adjuvant Radiation Therapy or Observation Informs Prognosis (2018) (0)
ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) (2018) (0)
A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813. (2016) (0)
Molecular Pathology: Poster#244 MUTATIONAL LANDSCAPE OF LACRIMAL GLAND CARCINOMAS AND IMPLICATIONS FOR TREATMENT (2014) (0)
Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion. (2014) (0)
Genome-Wide AnalysisofDNA CopyNumberAlterationsandLossofHeterozygosity in Intracranial Germ Cell Tumors (2013) (0)
Regional Recurrences, Hyams Grade, and Methylation Immune Score Analysis in Esthesioneuroblastoma (2019) (0)
IDH1 mutation status and outcome in clinical trials for recurrent glioblastoma. (2015) (0)
CBIO-14TARGETING PROTEASOME ACTIVITY WITH MARIZOMIB AS A THERAPEUTIC PERSPECTIVE FOR GLIOMA PATIENTS (2015) (0)
EPID-31. EFFICIENT STUDY OF SURGICALLY TREATED MENINGIOMA THROUGH CLINICAL DATA STANDARDIZATION (2019) (0)
CMET-30. COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS (2019) (0)
Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy , and in Combination With Lomustine , Versus Lomustine Alone in Patients With Recurrent Glioblastoma (2013) (0)
Reply to ‘Assembling the brain trust: the multidisciplinary imperative in neuro-oncology’ (2019) (0)
Phase I T rial o f A denovirus-Media ted p53 Gene T herapy f or Recurrent G lioma: B iological a nd C linical R esults (2003) (0)
Metabolic profiling of gliomas reveals distinct subgroups of tumors independent of IDH mutation status (2018) (0)
PRESENCE OF A DISTINCTIVE MYELOID POPULATION IS ASSOCIATED WITH THE INVASIVE TUMOR PHENOTYPE OBSERVED AFTER ANTI-ANGIOGENESIS THERAPIES. (2014) (0)
TMIC-07. HYPOXIC MICROENVIRONMENT CONFERS SPECIFIC ALTERATIONS IN DNA METHYLATION PROFILES IN GLIOBLASTOMA (2018) (0)
Chapter 24 – Mixed Gliomas (2005) (0)
NF-kBActivation Upregulates PKM2 Expression and Promotes Tumorigenesis (2018) (0)
Abstract 887: Development of a robust nanoimmunoassay and immunohistochemical assay for asparagine synthetase (2012) (0)
Galectin-1 expression in glioblastoma cell lines is associated with p53 gene expression: Implications with cell survival, invasive phenotype, presence in CD133 glioma cancer-stem cells (CSC) and poor patient survival (2008) (0)
Abstract 4671: Novel biological roles of the atypical WNT ligand, Norrin, on glioblastoma stem cells segregate with ASCL1 expression (2019) (0)
Intracranial Meningiomas: Predictor Factors of Clinical Behavior and Patients Outcome (2014) (0)
PATH-21. CLINICAL UTILITY OF DNA METHYLATION PROFILING FOR DIAGNOSIS OF CHALLENGING CENTRAL NERVOUS SYSTEM TUMORS: THE TORONTO EXPERIENCE (2019) (0)
Khalida WaniTerri S. ArmstrongElizabeth Vera-BolanosAditya RaghunathanDavid Ellison • Richard GilbertsonBrian VaillantStewart GoldmanRoger J. PackerMaryam FouladiIan Pollack • Tom MikkelsenMichael PradosAntonio OmuroRiccardo SoffiettiAlicia LedouxCharmaine Wilson • Lihong LongMark R. GilbertKen Alda (2012) (0)
BIOM-02. IDENTIFYING MGMT ALTERATIONS AS BIOMARKERS OF SURVIVAL IN LUNG ADENOCARCINOMA WITH BRAIN METASTASES (2020) (0)
MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS (2016) (0)
Extranodal Marginal Zone B-cell Lymphoma of the Dura Mater Mimicking Meningioma (2013) (0)
Overexpression of Sema3E and Sema5A in pilocytic astrocytoma (2017) (0)
OS3.6 Development and validation of a DNA methylome-based predictor of meningioma recurrence and meningioma recurrence score (2018) (0)
MNGO-09. PROGNOSTIC SIGNIFICANCE OF PRE-OPERATIVE ANEMIA AND LEUKOCYTOSIS ON RECURRENCE-FREE SURVIVAL IN MENINGIOMA (2016) (0)
287 COMBINING MOLECULAR AND CLINICAL FACTORS TO PREDICT SURVIVAL OF PATIENTS WITH GLIOBLASTOMA AND VALIDATION USING RTOG 0525 (2012) (0)
Pediatric Gliomas Presenting with Gliomatosis-Like Spread, Lack of Contrast Enhancement, EGFR Mutation, and TERT Promoter Variants. (2021) (0)
LGG-49. MOLECULAR ALTERATIONS IN PREGNANT ADOLESCENT AND YOUNG ADULT WOMEN WITH GLIOMA (2018) (0)
Loss at Chromosome 13q22.2 Indicates Poor Survival in a Group of Grade 2 and Grade 3 Astrocytomas (2006) (0)
Abstract 5214: Functional interaction between foxm1 and β-catenin (2012) (0)
EXTH-65. USING METHYLATION PROFILES TO GUIDE THE REPURPOSING OF CHEMOTHERAPIES AGAINST HIGH-RISK MENINGIOMAS (2020) (0)
GENE-38. DISRUPTED ENDOTHELIAL CELL GENE EXPRESSION PROFILE PREDICTS GBM CLINICAL RESPONSE TO ANTI-ANGIOGENIC THERAPY. (2017) (0)
Highlights from the literature (2022) (0)
The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care (2019) (0)
GENE-08. SCHWANNOMATOSIS SCHWANNOMAS HARBOR DISTINCT DNA METHYLATION PROFILES (2018) (0)
Survival under Heat Shock Stress Shock Factor 1 and Promotes Glioma Cells Forkhead Box M 1 Is Regulated by Heat Gene Regulation (2013) (0)
Establishing Prognostic DNA Methylation-Based Chordoma Subgroups in Tissue that are Detectable in Plasma (2022) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
Exploring cellular subpopulations in glioblastoma and matched organoids using single-cell RNA-seq (2018) (0)
Expression of c-met in Human Glioblastoma Does Not Correlate with Patient Survival or Clinical Radiation Response (2009) (0)
BIOM-62 SENSITIVE DETECTION AND DISCRIMINATION OF INTRACRANIAL TUMORS BY BLOOD (2020) (0)
TMIC-16. THE IMMUNO-PROTECTIVE FUNCTION OF GLIOMA-ASSOCIATED BONE MARROW DERIVED CELLS DEPENDS ON THE STAGE OF TUMOR GROWTH AND IS INFLUENCED BY TREATMENT WITH MINOCYCLINE (2017) (0)
ME-03BONE MARROW DERIVED MICROGLIA AND THEIR FUNCTION WITHIN TUMOR MICROENVIRONMENT. (2014) (0)
2504 ORAL Networking of endogenous modulators of nuclear factor-kappaB in predicting outcome in high-grade gliomas (2007) (0)
LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS (2018) (0)
MPTH-25AN 18-GENE EXPRESSION SIGNATURE PREDICTS RECURRENCE-FREE SURVIVAL IN MENINGIOMA (2015) (0)
OTHR-09. IDENTIFYING EPIGENETIC SIGNATURES IN LUNG ADENOCARCINOMAS THAT PREDICT DEVELOPMENT OF BRAIN METASTASIS (2019) (0)
Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. (2021) (0)
EPCO-01. LUNG ADENOCARCINOMA BRAIN METASTASIS PREDICTION, PREVENTION, AND NON-INVASIVE DIAGNOSIS USING METHYLATION SIGNATURES WITHIN TISSUE AND CIRCULATING TUMOUR DNA (2020) (0)
P2.03b-089 CD1C in Lung Adenocarcinoma: Prognosis and Cellular Origin: Topic: Biomarkers (2017) (0)
DISEASE MODELS Drug Discovery Today : Disease Models (2006) (0)
Exploring Therapeutic Targets in Schwannoma Through Integrative Analysis (2014) (0)
STEM-20MAPPING DYNAMICS OF CELL DIVISION AND GENE EXPRESSION AT THE SINGLE CELL LEVEL TO UNDERSTAND GLIOMA CELL STATES (2015) (0)
Podoplanin expression is an independent predictor of survival in malignant gliomas (2007) (0)
Abstract #5526: MSH6 somatic mutations in mediating temozolomide resistance in recurrent glioblastomas (2009) (0)
GROWTH PROPERTIES OF EARLY PASSAGE HUMAN FETAL ASTROCYTES EXPRESSING HUMAN PAPILLOMA VIRUS (HPV) ONCOPROTEINS (1996) (0)
Whole Genome Expression Profiling of Epithelial-Myoepithelial Carcinoma of Salivary Glands (2014) (0)
PATH-25. SURVIVAL STRATIFICATION OF IDH MUTANT GLIOMA USING METHYLATION AND mRNA ANALYSIS OF HOX GENES (2018) (0)
Cowden disease with Lhermitte-Duclos disease (2004) (0)
CSIG-23. CIC PROTEIN INSTABILITY DRIVES CANCER PHENOTYPES IN GLIOBLASTOMA (2017) (0)
Podoplanin Expression is Prognostic for Survival of Patients with Squamous Cell Carcinoma of the Cervix Treated with Definitive Radiation Therapy (2009) (0)
TMOD-11. APPLICATION OF A NOVEL TRANSGENIC AND SYNGENEIC MOUSE MODELS OF HUMAN CLASSICAL GLIOBLASTOMA FOR DRUG SCREENING AND PRE-CLINICAL TRIALS (2020) (0)
Abstract 2974: Combating breast cancer brain metastasis by targeting Src family kinases (2012) (0)
Chapter 14 HUMAN GLIOMA DIAGNOSIS FROM GENE EXPRESSION DATA (0)
EP-03MOLECULAR CLASSIFICATION OF EPENDYMAL TUMORS ACROSS ALL CNS COMPARTMENTS, HISTOPATHOLOGICAL GRADES AND AGE GROUPS (2015) (0)
THOR METHYLATION PROVIDES INSIGHT INTO THE TELOMERE MAINTENANCE LANDSCAPE OF MALIGNANT GLIOMAS (2014) (0)
Recurrence-free Survival in Meningioma Patients Receiving Radiation (2008) (0)
PATH-46. AUTOMATED HISTOPATHOLOGIC CLASSIFICATION OF BRAIN TUMORS USING ARTIFICIAL INTELLIGENCE (2017) (0)
CONTRIBUTION OF MICROGLIA TO RADIORESISTANCE AND MESENCHYMAL DIFFERENTIATION IN GLIOBLASTOMA (2011) (0)
KRAS Amplification in a 73-Year-Old Man with Adenocarcinoma of Lung (2014) (0)
Abstract A08: Chromothripsis and gene-specific copy number aberrations associated with mutation of IDH1 in glioma (2013) (0)
Genome-Wide Analysis of DNACopyNumber Alterations and Loss of Heterozygosity in Intracranial Germ Cell Tumors (2014) (0)
Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas (2017) (0)
differentiation in malignant glioma The transcriptional coactivator TAZ regulates mesenchymal Material Supplemental (2011) (0)
GENE-09. FUNCTIONAL GENOMIC ELEMENTS DEFINED BY DNA METHYLATION CAN DISTINGUISH MENINGIOMA SUBGROUPS (2018) (0)
Thanks to authors and peer reviewers (2007) (0)
Therapy Cultured Glioma Cells : Implications for Combined Modality Ionizing Radiation Inhibits Chemotherapy-induced Apoptosis in Updated (2006) (0)
Reviewer Acknowledgements 2018 (2018) (0)
HER2 Assessment by MIP Microarray in a Breast Cancer Patient with Equivocal HER2 Status (2016) (0)
Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study (2019) (0)
Abstract 3313: A proliferating population of glioma stem-like cells as characterized by expression of the cell surface glycoprotein CD58 (2011) (0)
Vancomycin Reduces Surgical-site Infections After Craniotomy : A Prospective , Controlled Study (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kenneth D. Aldape?

Kenneth D. Aldape is affiliated with the following schools:

Sahlgrenska Academy
Institute of Cancer Research
Yale University
National Cheng Kung University
MD Anderson Cancer Center
University of California, Los Angeles
Baylor College of Medicine
Johns Hopkins University
University of Toronto
University of California, San Francisco
Massachusetts General Hospital
Duke University
University of Minho

Kenneth D. Aldape's Academic­Influence.com Rankings

Kenneth D. Aldape's Degrees

Why Is Kenneth D. Aldape Influential?

Kenneth D. Aldape's Published Works

Published Works

What Schools Are Affiliated With Kenneth D. Aldape?

Kenneth D. Aldape's AcademicInfluence.com Rankings